NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 247 filers reported holding NEKTAR THERAPEUTICS in Q1 2022. The put-call ratio across all filers is 1.00 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $736 | -15.8% | 230 | 0.0% | 0.00% | – |
Q2 2022 | $874 | -29.5% | 230 | 0.0% | 0.00% | – |
Q1 2022 | $1,240 | -80.9% | 230 | -52.1% | 0.00% | – |
Q4 2021 | $6,485 | -24.8% | 480 | 0.0% | 0.00% | – |
Q3 2021 | $8,621 | +79.4% | 480 | +71.4% | 0.00% | – |
Q2 2021 | $4,805 | -28.3% | 280 | -16.4% | 0.00% | – |
Q1 2021 | $6,700 | +17.6% | 335 | 0.0% | 0.00% | – |
Q4 2020 | $5,695 | +2.5% | 335 | 0.0% | 0.00% | – |
Q3 2020 | $5,558 | -67.4% | 335 | -54.4% | 0.00% | -100.0% |
Q2 2020 | $17,023 | +29.7% | 735 | 0.0% | 0.00% | 0.0% |
Q1 2020 | $13,120 | -17.3% | 735 | 0.0% | 0.00% | 0.0% |
Q4 2019 | $15,865 | +18.5% | 735 | 0.0% | 0.00% | 0.0% |
Q3 2019 | $13,388 | -29.7% | 735 | +37.4% | 0.00% | -50.0% |
Q2 2019 | $19,035 | +18.0% | 535 | +11.5% | 0.00% | 0.0% |
Q1 2019 | $16,128 | -6.5% | 480 | -8.6% | 0.00% | 0.0% |
Q4 2018 | $17,257 | -46.1% | 525 | 0.0% | 0.00% | -50.0% |
Q3 2018 | $32,004 | +12.0% | 525 | -10.3% | 0.00% | 0.0% |
Q2 2018 | $28,566 | – | 585 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
CM Management, LLC | 50,000 | $858,000 | 0.62% |
Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |